29,361 Shares in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Bought by Schroder Investment Management Group

Schroder Investment Management Group bought a new stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 29,361 shares of the company's stock, valued at approximately $1,488,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in CRNX. Vanguard Group Inc. boosted its holdings in shares of Crinetics Pharmaceuticals by 44.6% in the fourth quarter. Vanguard Group Inc. now owns 9,089,391 shares of the company's stock valued at $464,741,000 after acquiring an additional 2,801,736 shares in the last quarter. SG Americas Securities LLC lifted its position in Crinetics Pharmaceuticals by 4,084.6% in the fourth quarter. SG Americas Securities LLC now owns 542,446 shares of the company's stock worth $27,735,000 after purchasing an additional 529,483 shares during the period. Franklin Resources Inc. boosted its stake in Crinetics Pharmaceuticals by 61.4% during the 3rd quarter. Franklin Resources Inc. now owns 1,390,110 shares of the company's stock valued at $73,815,000 after purchasing an additional 528,688 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Crinetics Pharmaceuticals by 10.1% during the 3rd quarter. Geode Capital Management LLC now owns 1,848,133 shares of the company's stock valued at $94,458,000 after purchasing an additional 169,746 shares during the period. Finally, Segall Bryant & Hamill LLC bought a new stake in shares of Crinetics Pharmaceuticals in the 4th quarter worth $7,690,000. 98.51% of the stock is currently owned by institutional investors.

Remove Ads

Crinetics Pharmaceuticals Price Performance

NASDAQ CRNX traded up $2.26 on Friday, hitting $29.11. 1,379,285 shares of the stock were exchanged, compared to its average volume of 851,237. The company's 50-day moving average price is $33.46 and its two-hundred day moving average price is $45.59. Crinetics Pharmaceuticals, Inc. has a 52-week low of $24.10 and a 52-week high of $62.53. The company has a market capitalization of $2.71 billion, a price-to-earnings ratio of -7.80 and a beta of 0.37.

Crinetics Pharmaceuticals (NASDAQ:CRNX - Get Free Report) last issued its earnings results on Thursday, February 27th. The company reported ($0.88) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.04. Equities analysts predict that Crinetics Pharmaceuticals, Inc. will post -3.73 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, insider Dana Pizzuti sold 2,515 shares of the firm's stock in a transaction that occurred on Wednesday, March 19th. The shares were sold at an average price of $34.20, for a total transaction of $86,013.00. Following the completion of the sale, the insider now directly owns 72,233 shares in the company, valued at approximately $2,470,368.60. This trade represents a 3.36 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Richard Scott Struthers sold 17,338 shares of the business's stock in a transaction that occurred on Wednesday, March 19th. The shares were sold at an average price of $34.20, for a total transaction of $592,959.60. Following the transaction, the chief executive officer now directly owns 329,147 shares in the company, valued at $11,256,827.40. The trade was a 5.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 32,015 shares of company stock worth $1,119,263. 6.00% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

CRNX has been the subject of several research reports. TD Cowen assumed coverage on Crinetics Pharmaceuticals in a research note on Tuesday, February 11th. They set a "buy" rating for the company. Wolfe Research started coverage on shares of Crinetics Pharmaceuticals in a research report on Tuesday, February 4th. They set a "peer perform" rating for the company. Stifel Nicolaus began coverage on shares of Crinetics Pharmaceuticals in a report on Tuesday, March 25th. They issued a "buy" rating and a $60.00 target price on the stock. JMP Securities restated a "market outperform" rating and set a $87.00 target price on shares of Crinetics Pharmaceuticals in a report on Monday, December 16th. Finally, Jefferies Financial Group raised Crinetics Pharmaceuticals from a "hold" rating to a "buy" rating and set a $55.00 price target on the stock in a report on Wednesday, January 22nd. One investment analyst has rated the stock with a hold rating and twelve have given a buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $73.00.

Crinetics Pharmaceuticals Profile

Crinetics Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors.